The opioid epidemic has increased hospital admissions for serious infections related to opioid abuse. Our findings demonstrate addiction medicine consultation is associated with increased treatment for opioid use disorder (OUD), greater likelihood of completing antimicrobial therapy, and reduced readmissions among patients with OUD and serious infections requiring hospitalization.
Synthetic cannabinoids have recently gained popularity as a recreational drug because they are believed to result in a marijuana-like high. This investigation compared synthetic cannabinoids and marijuana exposures reported to a large statewide poison center system. Synthetic cannabinoid and marijuana exposures reported to Texas poison centers during 2010 were identified. The distribution of exposures to the two agents with respect to various demographic and clinical factors were compared by calculating the rate ratio (RR) of the synthetic cannabinoid and marijuana percentages for each subgroup and 95% confidence interval (CI). The proportion of synthetic cannabinoid and marijuana exposures, respectively, were 87.3% and 46.5% via inhalation (RR 1.88, 95% CI 1.38–2.61), 74.9% and 65.7% in male (RR 1.14, 95% CI 0.87–1.51), 40.2% and 56.6% age ≤19 years (RR 0.71, 95% CI 0.52–0.98), 79.2% and 58.6% occurring at a residence (RR 1.35, 95% CI 1.02–1.82), 8.4% and 16.2% managed on-site (RR 0.52. 95% CI 0.28–1.00), and 59.3% and 41.4% with serious medical outcomes (RR 1.43, 95% CI 1.03–2.05). Compared to marijuana, synthetic cannabinoid exposures were more likely to be used through inhalation, to involve adults, to be used at a residence, and to result in serious outcomes.
1 September 2012 in The American Journal of Emergency Medicine
Illicit opioids, consisting largely of fentanyl, novel synthetic opioids, and adulterants, are the primary cause of drug overdose fatality in the United States. Xylazine, an alpha-2 adrenergic agon...
Cannabinoid hyperemesis syndrome (CHS) is characterized by symptoms of cyclic abdominal pain, nausea, and vomiting in the setting of prolonged cannabis use. The transient receptor potential vanilloid 1 (TRPV1) receptor may be involved in this syndrome. Topical capsaicin is a proposed treatment for CHS; it binds TRPV1 with high specificity, impairing substance P signaling in the area postrema and nucleus tractus solitarius via overstimulation of TRPV1. This may explain its apparent antiemetic effect in this syndrome. We describe a series of thirteen cases of suspected cannabis hyperemesis syndrome treated with capsaicin in the emergency departments of two academic medical centers. A query of the electronic health record at both centers identified thirteen patients with documented daily cannabis use and symptoms consistent with CHS who were administered topical capsaicin cream for symptom management. All 13 patients experienced symptom relief after administration of capsaicin cream. Topical capsaicin was associated with improvement in symptoms of CHS after other treatments failed.